Literature DB >> 24638132

Multiple sclerosis: TOWER confirms the efficacy of oral teriflunomide in MS.

Aiden Haghikia1, Ralf Gold1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24638132     DOI： 10.1038/nrneurol.2014.42

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

Authors:  Patrick Vermersch; Anna Czlonkowska; Luigi M E Grimaldi; Christian Confavreux; Giancarlo Comi; Ludwig Kappos; Tomas P Olsson; Myriam Benamor; Deborah Bauer; Philippe Truffinet; Meg Church; Aaron E Miller; Jerry S Wolinsky; Mark S Freedman; Paul O'Connor
Journal:  Mult Scler       Date:  2013-10-14       Impact factor: 6.312

2.  Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial.

Authors:  M S Freedman; J S Wolinsky; B Wamil; C Confavreux; G Comi; L Kappos; T P Olsson; A Miller; H Benzerdjeb; H Li; C Simonson; P W O'Connor
Journal:  Neurology       Date:  2012-05-23       Impact factor: 9.910

3.  An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.

Authors:  Rodrigo A Fuentealba; Jayne Marasa; Marc I Diamond; David Piwnica-Worms; Conrad C Weihl
Journal:  Hum Mol Genet       Date:  2011-11-03       Impact factor: 6.150

4.  A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

Authors:  P W O'Connor; D Li; M S Freedman; A Bar-Or; G P A Rice; C Confavreux; D W Paty; J A Stewart; R Scheyer
Journal:  Neurology       Date:  2006-03-28       Impact factor: 9.910

5.  Suppression of experimental autoimmune neuritis by leflunomide.

Authors:  T Korn; K Toyka; H P Hartung; S Jung
Journal:  Brain       Date:  2001-09       Impact factor: 13.501

Review 6.  Pathophysiology of multiple sclerosis and the place of teriflunomide.

Authors:  R Gold; J S Wolinsky
Journal:  Acta Neurol Scand       Date:  2010-09-29       Impact factor: 3.209

7.  Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

Authors:  Paul O'Connor; Jerry S Wolinsky; Christian Confavreux; Giancarlo Comi; Ludwig Kappos; Tomas P Olsson; Hadj Benzerdjeb; Philippe Truffinet; Lin Wang; Aaron Miller; Mark S Freedman
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

8.  Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Christian Confavreux; Paul O'Connor; Giancarlo Comi; Mark S Freedman; Aaron E Miller; Tomas P Olsson; Jerry S Wolinsky; Teresa Bagulho; Jean-Luc Delhay; Deborah Dukovic; Philippe Truffinet; Ludwig Kappos
Journal:  Lancet Neurol       Date:  2014-01-23       Impact factor: 44.182

Review 9.  Therapies for multiple sclerosis: translational achievements and outstanding needs.

Authors:  Aiden Haghikia; Reinhard Hohlfeld; Ralf Gold; Lars Fugger
Journal:  Trends Mol Med       Date:  2013-04-10       Impact factor: 11.951

10.  Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis.

Authors:  Amit Bar-Or; Mark S Freedman; Marcelo Kremenchutzky; Françoise Menguy-Vacheron; Deborah Bauer; Stefan Jodl; Philippe Truffinet; Myriam Benamor; Scott Chambers; Paul W O'Connor
Journal:  Neurology       Date:  2013-07-12       Impact factor: 9.910
  10 in total
  6 in total

1.  Teriflunomide Modulates Vascular Permeability and Microglial Activation after Experimental Traumatic Brain Injury.

Authors:  Karthik S Prabhakara; Daniel J Kota; Gregory H Jones; Amit K Srivastava; Charles S Cox; Scott D Olson
Journal:  Mol Ther       Date:  2018-07-05       Impact factor: 11.454

2.  Genome-wide CRISPR screens using isogenic cells reveal vulnerabilities conferred by loss of tumor suppressors.

Authors:  Xu Feng; Mengfan Tang; Merve Dede; Dan Su; Guangsheng Pei; Dadi Jiang; Chao Wang; Zhen Chen; Mi Li; Litong Nie; Yun Xiong; Siting Li; Jeong-Min Park; Huimin Zhang; Min Huang; Klaudia Szymonowicz; Zhongming Zhao; Traver Hart; Junjie Chen
Journal:  Sci Adv       Date:  2022-05-13       Impact factor: 14.957

Review 3.  Role of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosis.

Authors:  Zhong-Xiang Xie; Hong-Liang Zhang; Xiu-Juan Wu; Jie Zhu; Di-Hui Ma; Tao Jin
Journal:  Mediators Inflamm       Date:  2015-01-29       Impact factor: 4.711

Review 4.  Excitotoxins, Mitochondrial and Redox Disturbances in Multiple Sclerosis.

Authors:  Cecilia Rajda; Dániel Pukoli; Zsuzsanna Bende; Zsófia Majláth; László Vécsei
Journal:  Int J Mol Sci       Date:  2017-02-08       Impact factor: 5.923

5.  Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma.

Authors:  Yajie Yu; Jane Ding; Shunqin Zhu; Ahmet Alptekin; Zheng Dong; Chunhong Yan; Yunhong Zha; Han-Fei Ding
Journal:  Cell Death Dis       Date:  2021-08-30       Impact factor: 8.469

Review 6.  Multiple sclerosis--new treatment modalities.

Authors:  Rocco Totaro; Caterina Di Carmine; Carmine Marini; Antonio Carolei
Journal:  Indian J Med Res       Date:  2015-12       Impact factor: 2.375
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.